|
|
Profile
|
Delegates :
Dr. Toshiharu Furukawa |
|
Incorporated :
January 6 , 2020 |
Paid in Capital :
90 Million yen |
Employees :
人 |
Address :
Yotsuya 1-14-1, Shinjuku-ku TOKYO
〒160-0004
|
TEL/FAX :
/ |
URL：
https://www.ixgene.inc/en/ |
Attachment :
|
Mission/Background :
Our company’s name, “iXgene”, signifies the combination of two innovative technologies: the iPS cell technology and the genome editing technology. Our goal is the establishment of the platform technology for novel treatments against various cancers and rare diseases using diverse types of stem cells with enhanced functions produced from genome-edited iPS cells. The initial focus is on malignant brain tumors, and brain injuries resulting from trauma or stroke, with plans to expand to other types of cancers and diseases. |
|
Technology & Business
|
We are addressing these challenges in cell therapy and gene therapy by utilizing genome-edited induced pluripotent stem (iPS) cells.
For the treatment of intractable brain diseases, we have developed therapeutic Neural Stem Cells (NSCs) by introducing the CD-UPRT gene into iPS cells through genome editing and inducing their differentiation. In addition to the enhanced productivity achieved with iPS cells, we have introduced a suicide gene that converts prodrugs into cell-killing drugs, ensuring a high level of safety during the administration of cells into the brain.
Moreover, given the inherent ability of neural stem cells to sense and accumulate various chemokines secreted from brain tumors and damaged brain sites, they can serve as effective gene delivery vehicles.
We are advancing the development of therapeutic NSCs, integrating genome editing technology and iPS cell technology, as a novel solution for malignant brain tumors and brain dysfunction.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Therapeutic NSCs for malignant brain tumors (gliomas)
|
Discovery
|
We are developing a novel gene cell therapy for recurrent glioblastoma for which no existing treatment exists.
|
|
Therapeutic NSCs for brain injury
|
Discovery
|
Therapeutic NSCs are induced by differentiation from iPS cells and can be produced in mass production in a stable process.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
2023.10 Announcement of a three-way joint research agreement between iXgene, Keio University School of Medicine, and Sumitomo Pharma for the practical application of a treatment for malignant brain tumors using genome-edited iPS cells.
2023.01 Keio Innovation Initiative/University of Tokyo Collaborative Creation Platform Development/MSF Capital Partners/Green Core to carry out third-party allotment capital increase totaling 600 million yen.
|
|
Alliance strategy
|
Although our company is a very small startup, we are committed to advancing forward based on the accumulated scientific validation of genome-edited iPS cells, striving to deliver significant value to patients and society. We sincerely welcome researchers and investors who share our mission to join our team so that we work together towards the realization of iXgene's mission.
|
|
|